Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRM-823 in Advanced or Metastatic Solid Tumors
NCT07182149Phase 1Recruiting
- Sponsor
- Normunity
- Start
- Oct 2025
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NRM-823 in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC) and 7 more, sponsored by Normunity. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of dose-limiting toxicities. Started Oct 2025; status: recruiting.
02
Drugs
NRM-823
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07182149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182149.